立方制药(003020) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 reached ¥355,783,285.61, an increase of 38.59% compared to the same period last year[2] - Net profit attributable to shareholders was ¥41,548,837.36, reflecting a 3.24% increase year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥38,700,215.52, up by 1.50% from the previous year[2] - Total operating revenue for the period was ¥1,125,115,398.63, a decrease of 26.2% compared to ¥1,524,501,653.00 in the previous period[16] - Net profit for the period was ¥115,656,533.48, a decline of 33.1% from ¥172,830,684.68 in the same period last year[18] - Basic and diluted earnings per share were both ¥0.63, down from ¥0.91 in the previous year[18] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,554,823,965.84, representing a 2.86% increase from the end of the previous year[2] - The total assets increased from CNY 2,483,679,575.17 to CNY 2,554,823,965.84, reflecting a growth of about 2.9%[14] - Total liabilities rose to ¥630,163,196.36 from ¥610,181,560.50 at the beginning of the period[15] - The company's long-term borrowings increased from CNY 31,014,208.33 to CNY 59,646,667.50, an increase of approximately 92.5%[14] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥126,676,762.66, showing a significant increase of 104.37% year-on-year[8] - Cash flow from operating activities generated a net amount of ¥126,676,762.66, an increase from ¥61,983,227.36 in the prior period[19] - The net cash flow from investment activities was -234,972,099.35, an improvement from -481,095,787.26 in the previous period, indicating a reduction in cash outflow[20] - Total cash inflow from financing activities was 29,117,727.92, down from 115,544,527.74 in the previous period, reflecting a significant decrease in financing received[20] - The ending balance of cash and cash equivalents was 319,783,092.31, a decrease from 502,722,212.82 at the beginning of the period[20] Expenses - The company reported a 58.50% decrease in operating costs for the first nine months of 2024 compared to the same period in 2023, primarily due to the exclusion of a subsidiary from consolidation[6] - The company’s management expenses increased by 37.25% year-on-year, mainly due to the consolidation of Hefei Nuoruite[7] - Research and development expenses were ¥53,806,835.68, a decrease of 10.4% compared to ¥59,933,416.45 in the previous period[17] - Sales expenses increased to ¥528,538,993.22, up 24% from ¥426,697,055.82 in the prior period[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,634[9] - Total equity attributable to shareholders of the parent company increased to ¥1,731,705,401.75 from ¥1,685,526,341.61 at the beginning of the period[15] Strategic Changes - The company's industry classification was changed to "Pharmaceutical Manufacturing" as of September 30, 2024, reflecting its strategic focus[12] - The company’s revenue from the pharmaceutical industry accounted for 60.92% of total revenue, following a strategic shift from wholesale to pharmaceutical manufacturing[11] - The company’s application for the registration of the raw material drug Paliperidone was accepted during the reporting period[11] Investment Activities - The company paid 383,412,054.79 in cash for investments, down from 545,000,000.00, reflecting a reduction in investment expenditures[20] - The company received 275,000,118.72 in cash from investment recoveries, down from 360,000,000.00 in the previous period, indicating a decline in investment recoveries[20] - The cash flow from investment activities totaled 281,061,137.75, compared to 453,137,668.12 in the previous period, showing a decrease in overall investment cash inflow[20] Other Financial Metrics - The basic earnings per share for Q3 2024 was ¥0.2169, down by 16.58% compared to the same period last year[2] - The weighted average return on equity was 2.43%, a decrease of 0.06% from the previous year[2] - Deferred income decreased to ¥18,271,309.95 from ¥20,163,577.11 at the beginning of the period[15] - The company reported a cash flow impact from exchange rate changes of -8,840.68, contrasting with a positive impact of 45,288.28 in the previous period[20] - The company did not undergo an audit for the third quarter report, indicating that the financial results are unaudited[20]